Department of Hematology, Postgraduate Program in Internal Medicine, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Department of Pathology, Stanford University School of Medicine, Stanford, USA.
Ann Oncol. 2012 Mar;23(3):736-742. doi: 10.1093/annonc/mdr157. Epub 2011 May 20.
A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL).
The aim of the present study was to verify the relationship between the number of CD68+ and CD163+ macrophages with clinical outcomes in a cohort of 265 well-characterized patients with cHL treated uniformly with the standard doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen. Two pairs of hematopathologists carried out independent pathological evaluations of tissue microarray slides.
There were no associations between clinical characteristics and the expression of CD68 or CD163. However, higher levels of CD68 and CD163 expression were correlated with the presence of Epstein-Barr virus-positive Hodgkin tumor cells (P = 0.01 and 0.037, respectively). The expression of CD68 or CD163 was not associated with either the PFS or the DSS.
CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL.
最近的一项研究表明，在经典霍奇金淋巴瘤（cHL）患者中，CD68+巨噬细胞数量的增加与初次治疗失败、无进展生存期（PFS）和疾病特异性生存期（DSS）缩短相关。
本研究的目的是在 265 例经标准多柔比星、博来霉素、长春碱和达卡巴嗪化疗方案治疗的 cHL 患者队列中，验证 CD68+和 CD163+巨噬细胞数量与临床结局的关系。两名配对的血液病理学家对组织微阵列载玻片进行了独立的病理评估。
CD68 或 CD163 的表达与临床特征之间没有关联。然而，CD68 和 CD163 的高表达与 EBV 阳性霍奇金肿瘤细胞的存在相关（P=0.01 和 0.037）。CD68 或 CD163 的表达与 PFS 或 DSS 均无相关性。
CD68 和 CD163 的表达需要进一步评估，然后才能推荐其用于 cHL 患者的预后分层。
